SPRY earnings analysis
What we found in SPRY's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ARS reported second-quarter revenue of $33.658 million, a substantial sequential and year-over-year rebound, but diluted EPS was negative $0.63 and the filing does not provide enough information to calculate current gross or operating margin or free cash flow. Management highlighted second-half 2026 cash-based SG&A and R&D expenses of $100 million-$110 million and a path to cash-flow breakeven by the end of 2027. The outlook is offset by reliance on a single approved product, $100.0 million of debt subject to a $25.0 million minimum liquidity covenant, and newly disclosed litigation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue rebounded sharply
- Second-quarter revenue was $33.658 million, up from $23 million in the immediately preceding quarter and $16 million in the prior-year quarter.
- Expense reset targets breakeven
- Management outlined second-half 2026 aggregate SG&A and R&D expense of $114 million-$126 million, including cash-based expenses of $100 million-$110 million, supporting a stated path to cash-flow breakeven by the end of 2027.
- Reported liquidity runway
- The company reported that existing cash and cash equivalents are expected to fund planned operations for at least three years, although management cautioned that the estimate could prove incorrect.
- Broad patent position
- ARS owns, co-owns or exclusively licenses eight issued U.S. patents directed to neffy and its uses, in addition to granted patents in multiple foreign jurisdictions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Single-product concentration
- The filing adds a risk factor stating that the company is highly dependent on successful commercialization of neffy, its only approved product. Second-quarter revenue was $33.658 million, underscoring the concentration of the current commercial base.
- Debt and liquidity covenant risk
- As of June 30, 2026, outstanding Credit Agreement principal was $100.0 million, and the agreement requires at least $25.0 million of unrestricted cash and cash equivalents at all times. Failure to comply could permit lenders to accelerate repayment and pursue collateral.
- New TCPA litigation
- The filing adds disclosure of a putative TCPA class action filed on July 10, 2026, alleging unsolicited fax advertising for neffy; the complaint is Civil Action No. 3:26-cv-01339 and the outcome could materially affect operations and financial condition.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.63
What they said about what is next.
No comparable prior outlook was disclosed. Management provided second-half 2026 aggregate SG&A and R&D expense guidance of $114 million-$126 million, including approximately $14 million-$16 million of stock-based compensation and $100 million-$110 million of cash-based expenses, and described a path to cash-flow breakeven by the end of 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, significantly increasing from $8 million in Q1 2025. However, the company continues to experience a net loss of $60.6 million, widening from $33.9…
- 10-K · March 9, 2026
- ARS Pharmaceuticals reported a decline in total revenue for 2025, totaling $84.3 million, down 5% from 2024's revenue of $89.1 million, mainly due to a significant drop in revenue from collaboration agreements. The…
- 10-Q · November 10, 2025
- ARS Pharmaceuticals reported Q3 2025 results showing significant revenue growth with total revenue of $32.5 million, up from $2.1 million in the same quarter of the previous year. Despite the revenue surprise, the…
- 10-Q · August 13, 2025
- ARS Pharmaceuticals, Inc. reported a significant increase in revenue for Q2 2025, reaching $15.7 million, compared to just $0.5 million in the same quarter of the previous year, driven largely by the launch of its…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SPRY makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever